Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


OTCPK:ATBPF - Post by User

Comment by mstrmndon Jun 10, 2020 5:09pm
211 Views
Post# 31135692

RE:at 0.40 financing

RE:at 0.40 financingWhy are you reposting junk?  

mingzhu wrote: TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (the “Underwriters”), pursuant to which the Underwriters have agreed to purchase 62,500,000 units of the Company (the “Units”) at a price of $0.40 per Unit for gross proceeds of $25,000,000 (the “Offering”). Each Unit shall consist of one common share of the Company (a “Share”) and one-third (1/3) of one Common Share purchase warrant (a “Warrant”), each whole Warrant exercisable for one common share at a price of $0.60 per share for a period of 24 months. In addition, the Underwriters will have the option, exercisable until 30 days after the closing date, to acquire up to that number of additional Units equal to 15% of the Units sold and/or additional Warrants equal to 15% of the number of Warrants sold (the “Over-Allotment Option”). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering would be $28,750,000.


<< Previous
Bullboard Posts
Next >>